Lenmeldy, GLP-1s and Oprah, autoimmune disease

Adam’s Biotech Scorecard is a new newsletter offering insights on the biotech industry by senior reporter Adam Feuerstein. In the latest issue, topics include FDA approval for Akebia Therapeutics’ Vafseo, Gilead Sciences licensing an experimental cancer drug, and the world’s costliest drug, Lenmeldy, priced at $4.25 million. The newsletter also discusses immune senescence and potential causes of kidney autoimmune diseases. The content covers important developments in the biotech field and provides in-depth analysis on key issues. Subscribers can sign up to receive the newsletter in their inbox for exclusive access to this information.

Source link

error: Content is protected !!